SecSonar.com

Catalyst Pharmaceuticals, Inc. (CPRX)

Catalyst Pharmaceuticals, Inc. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.

Catalyst Pharmaceuticals, Inc. (CPRX) is a Biotechnology company based in US with a market capitalization of $3.8B. Revenue grew 19.8% year-over-year and the company generated $208.6M in free cash flow. This page tracks CPRX's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.

US · 181 employees · IPO Nov 8, 2006

Valuation

Valuation & price

$31.18 · as of May 17, 2026 · -1.0% vs 52w high

18.5

P/E ratio

Latest-FY diluted EPS

4.02

P/B ratio

Market cap ÷ book equity

—

Dividend yield

Price — last 12 months

$31.50$25.51$19.52Jul 25Dec 25Jul 26Jul 7, 25$20.95Jul 9, 25$21.63Jul 11, 25$21.81Jul 15, 25$20.95Jul 17, 25$21.45Jul 21, 25$21.01Jul 23, 25$21.57Jul 25, 25$20.97Jul 29, 25$21.02Jul 31, 25$21.33Aug 4, 25$21.73Aug 6, 25$21.79Aug 11, 25$19.68Aug 13, 25$20.19Aug 15, 25$20.23Aug 19, 25$20.25Aug 21, 25$20.56Aug 25, 25$20.62Aug 27, 25$20.19Aug 29, 25$20.59Sep 3, 25$19.79Sep 5, 25$20.29Sep 9, 25$20.00Sep 11, 25$20.25Sep 16, 25$20.07Sep 18, 25$20.40Sep 22, 25$20.05Sep 24, 25$19.70Sep 26, 25$19.52Sep 30, 25$19.70Oct 2, 25$20.84Oct 6, 25$20.73Oct 8, 25$20.39Oct 10, 25$20.36Oct 14, 25$20.31Oct 16, 25$20.53Oct 21, 25$21.43Oct 23, 25$20.73Oct 27, 25$21.39Oct 29, 25$21.01Oct 31, 25$21.27Nov 4, 25$21.34Nov 6, 25$20.99Nov 10, 25$21.56Nov 12, 25$22.78Nov 14, 25$23.18Nov 18, 25$22.66Nov 20, 25$22.77Nov 25, 25$23.59Nov 28, 25$23.41Dec 2, 25$22.62Dec 4, 25$23.08Dec 8, 25$23.16Dec 10, 25$22.80Dec 12, 25$23.62Dec 16, 25$24.19Dec 18, 25$23.67Dec 22, 25$24.31Dec 24, 25$24.45Dec 29, 25$24.06Jan 2, 26$23.15Jan 6, 26$22.58Jan 8, 26$22.60Jan 12, 26$23.22Jan 14, 26$23.17Jan 16, 26$22.70Jan 21, 26$24.13Jan 23, 26$23.58Jan 27, 26$24.07Jan 29, 26$24.58Feb 2, 26$25.00Feb 4, 26$25.06Feb 9, 26$24.45Feb 11, 26$23.93Feb 13, 26$24.33Feb 18, 26$24.29Feb 20, 26$24.30Feb 24, 26$24.19Feb 26, 26$24.88Mar 2, 26$23.88Mar 4, 26$24.69Mar 6, 26$24.24Mar 10, 26$24.77Mar 12, 26$23.39Mar 17, 26$23.33Mar 19, 26$22.33Mar 23, 26$23.32Mar 25, 26$23.80Mar 27, 26$23.40Mar 31, 26$24.76Apr 2, 26$24.69Apr 7, 26$24.99Apr 9, 26$25.60Apr 13, 26$25.34Apr 15, 26$25.85Apr 17, 26$26.26Apr 22, 26$25.94Apr 24, 26$27.37Apr 28, 26$29.44Apr 30, 26$28.13May 4, 26$28.94May 6, 26$30.52May 8, 26$31.15May 12, 26$31.14May 14, 26$31.16May 18, 26$31.23May 20, 26$31.25May 22, 26$31.26May 28, 26$31.29Jun 1, 26$31.27Jun 3, 26$31.28Jun 5, 26$31.27Jun 9, 26$31.34Jun 11, 26$31.37Jun 15, 26$31.37Jun 17, 26$31.40Jun 22, 26$31.38Jun 24, 26$31.42Jun 26, 26$31.50Jul 2, 26$31.45
$19.1352-week range$31.50
Loading valuation history…

Fundamentals

Key fundamentals

$3.8B

Market cap

19.8%

Revenue growth (YoY)

85.2%

Gross margin

$208.6M

Free cash flow (USD)

-$706.4M

Net debt

Net cash position

3.2%

Share dilution

3/5

Graham criteria passed

Defensive-investor screen

Healthcare

Sector

Trajectory

Long-term trends

Revenue by year

2016 → 2025

FY 2016$0.00FY 2017$0.00FY 2018$500.0KFY 2019$102.3MFY 2020$119.1MFY 2021$140.8MFY 2022$214.2MFY 2023$398.2MFY 2024$491.7MFY 2025$589.0M
$0$589M

Free cash flow by year

2016 → 2025

FY 2016$-18.1MFY 2017$-13.7MFY 2018$-25.8MFY 2019$34.6MFY 2020$45.0MFY 2021$59.4MFY 2022$116.0MFY 2023$61.9MFY 2024$239.3MFY 2025$208.6M
-$18.1M$208.6M

Gross margin by year

2021 → 2025

FY 202184.5%FY 202283.9%FY 202387.0%FY 202486.0%FY 202585.2%
84.5%85.2%

Value screen

Graham defensive-investor tests

Computing the scorecard — refreshing any stale inputs…

0

Insider buys · 90 days

0

Insider sells · 90 days

Earnings

Last report: 10-Q filed May 11, 2026

Next expected: not yet scheduled

On the tape

Recent SEC & insider activity

  • 8-K eventClinical Study ResultsJun 30, 2026Filing
  • 8-K eventMerger Agreement UpdateJun 23, 2026Filing
  • Quarterly report10-Q FiledMay 11, 2026Filing
  • 8-K eventEarnings ReleaseMay 11, 2026Filing
  • 8-K eventMerger AgreementMay 7, 2026Filing
  • Annual report10-K FiledApr 30, 2026Filing

Questions

Frequently asked questions

What is Catalyst Pharmaceuticals, Inc.'s market cap?

Catalyst Pharmaceuticals, Inc. (CPRX) has a market capitalization of $3.8B.

What is CPRX's P/E ratio?

CPRX trades at a price-to-earnings ratio of 18.5, based on its latest fiscal-year diluted earnings per share and the most recent cached price.

What is CPRX's price-to-book (P/B) ratio?

CPRX trades at 4.02 times book value per share.

Are insiders buying CPRX stock?

SEC Form 4 filings show no open-market insider buys at Catalyst Pharmaceuticals, Inc. in the last 90 days (0 sells).

Same arena

Related companies in Biotechnology

DNTH

Dianthus Therapeutics, Inc.

$3.8B

VCYT

Veracyte, Inc.

$3.8B

CRNX

Crinetics Pharmaceuticals, Inc.

$3.7B

ACAD

ACADIA Pharmaceuticals Inc.

$3.7B

NAMS

NewAmsterdam Pharma Company N.V.

$3.9B

KNSA

Kiniksa Pharmaceuticals, Ltd.

$3.7B

Timeline

Every filing, insider trade & earnings on a price-anchored timeline

Filing Analyzer

Search the actual 10-K / 10-Q text with AI research angles

News

Latest press coverage in one feed

Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.